JM1-24-3
JM1-24-3 is an anti-MUC18 mouse monoclonal antibody with a Kd value of 1.60e-9 M. JM1-24-3 reduces the phosphorylation levels of p-AKT (Ser473) and p-mTOR (Ser2448) in a time-dependent manner. JM1-24-3 exhibits anticancer activity against melanoma. JM1-24-3 can be used in studies related to metastatic melanoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Species Reactivity
Human
In Vitro
JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells[1].
JM1-24-3 (0.001-10 μg/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates[1].
JM1-24-3 binds to recombinant MUC18 with a high affinity (KD = 1.60E-09)[1].
JM1-24-3 (0.001-1 μg/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 μg/mL; 24 h) reduces binding by 40.7%[1].
JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins[1].
JM1-24-3 (150 μg/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation[1].
JM1-24-3 (150 μg/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation[1].
JM1-24-3 (150 μg/mL) inhibits invasion of WM266-4 melanoma cells by 52%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A375, A2058, WM266-4
-
Concentration:150 μg/mL
-
Incubation Time:7 days
-
Result:Significantly inhibited proliferation of all three cell lines: A375 by 52%, A2058 by 76%, and WM266-4 by 46% (p < 0.01 for all) compared to irrelevant mAb treatment.
-
Cell Line:WM266-4
-
Concentration:150 μg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced WM266-4 cell migration by 58% (p < 0.01) compared to irrelevant mAb treatment.
In Vivo
JM1-24-3 (6 mg/kg; i.p.; twice weekly; administered 1 day prior to tumor cell injection and continued until day 45) significantly reduces the average number of melanoma lung metastases to 3.8 colonies per mouse[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic nude (nu/nu) (male, 4-8 weeks old, subcutaneous xenograft model via injection of 1 million WM266-4 melanoma cells)[1]
-
Dosage:6 mg/kg
-
Administration:i.p.; twice a week; 45 days
-
Result:Reduced tumor volume to 46.8 mm3 (p < 0.01).
Caused no observable toxicity, including no reduction in body weight.
Gene ID
Accession
Target
MUC18/MCAM/CD146
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Pureté et documentation
Références
[1]. Feng R, et al. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020;39(1):273. Published 2020 Dec 5. [Content Brief]
[2]. Zhang F, et al. MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. J Transl Med. 2025;23(1):473. Published 2025 Apr 24. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)